Genotropin Original 16 IU Pfizer Labs | TPT0143
Somatotropics. Genotropin from Pfizer Labs interacts with specific membrane receptors, increases intracellular cAMF content and activates proteinkinases and protein synthesis. It enhances bone metabolism and accelerates the linear growth of the skeleton, maintains the normal structure of the body, stimulates muscle growth, muscle strength, cardiac output and helps mobilize fat. Genotropin increases the serum concentration of insulin, insulin-like growth factor (IRF-1) and its binding protein (IRFSB-3). The number of receptors that bind LDLs in the liver is increasing and the serum lipid and lipoprotein profiles are changing. Genotropin from Pfizer Labs inhibits the release of sodium, potassium and phosphorus, increases physical endurance, regulates the balance of neurotransmitters in the brain, improves memory and improves vitality.
Release form and composition
Genotropin from Pfizer Labs - lyophilizate to prepare a solution for subcutaneous administration (per 1 ml of solution after mixing): 1 ml contains recombinant somatotropin (somatropin) 16 IU (5.3 mg), glycine 2 mg, manite 41 mg, anhydrous sodium dihydrophosphate 0.29 mg, anhydrous sodium phosphate 0.28 mg, m-cresol 3 mg, injection water up to 1 ml; in a box of 1 or 5 cartridges.
The hormones corticosteroids reduce the stimulating effect on growth.
How to take, course and dosage
P/k (a cartridge is placed in the Genotropin Foam injector beforehand, where automatic breeding takes place). The dose is selected individually depending on the weight or surface area of the body (taking into account the clinical effect, unwanted reactions and serum IGF-1 determination results).
Genotropin is administered with caution in case of diabetes mellitus (insulin dose correction may be required); untreated hypothyroidism (periodic examination of thyroid function, prescription of thyroid hormones is necessary); lameness in children, hypopituitarism (careful monitoring is recommended).
Symptoms of fluid retention (peripheral edema, arthralgia, myalgia, etc.) - these phenomena are moderate or weak, appear during the first months of treatment and decrease spontaneously or after a dose reduction; rare - benign intracranial hypertension, myositis; very rare - leukemia.
|Active ingredient, mg||5,3|
|Active ingredient, IU||16|